Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07325435 · ClinicalTrials.gov registry record · Phase 4
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
A Phase 4 study of Type 2 Diabetes (T2DM), sponsored by MaryAnn Banerji.
- Active
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07325435 is a Phase 4 study of Type 2 Diabetes (T2DM) that is active but no longer recruiting, run by MaryAnn Banerji. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07325435, a Phase 4 study of Type 2 Diabetes (T2DM), is active but no longer recruiting, sponsored by MaryAnn Banerji.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Minorities have higher rates of diabetes, poorer glucose control, and higher complications and mortality rates than white people. Several recently approved diabetes medicines improve cardiovascular and renal outcomes through two different mechanisms. This study will explore key determinants of blood glucose levels namely beta cell function after short-term randomized, parallel group treatment with FDA approved Glucagon-Like Peptide-1 Receptor Agonists¬ (GLP-1 RA), or FDA approved Sodium-Glucose co-Transporter-2 Inhibitor (SGLT-2i). Because diabetes in black people shows a unique ability to recover pancreatic insulin secretion, it is important to determine whether the effects of these drug classes differentially improve pancreatic beta cell function.
Conditions Studied
Interventions
- DRUG SGLT-2 inhibitor
- DRUG GLP1-RA
Study Locations (1)
New York
- SUNY Downstate Health Sciences University - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-12-21 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07325435
The ClinicalTrials.gov registry entry for NCT07325435 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MaryAnn Banerji, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which SGLT-2 inhibitor is the first listed.
NCT07325435 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07325435 about?
NCT07325435 is a clinical study titled "Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists". Minorities have higher rates of diabetes, poorer glucose control, and higher complications and mortality rates than white people. Several recently approved diabetes medicines improve cardiovascular and renal outcomes through two different mechanisms. This study will explore key determinants of blood...
What is the current status of trial NCT07325435?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2024-12-21. Estimated completion is 2028-06-30.
What conditions does trial NCT07325435 study?
This clinical trial studies the following conditions: Type 2 Diabetes (T2DM).
What interventions are being tested in trial NCT07325435?
The interventions under investigation include: SGLT-2 inhibitor (DRUG), GLP1-RA (DRUG).
Who is sponsoring clinical trial NCT07325435?
This trial is sponsored by MaryAnn Banerji, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07325435 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
RECRUITING · Phase 3
-
The GRoceries Aimed at Increasing Nutrition Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.